Agreement reached to expand distribution of avanafil for ED
Petros also announced that it has received positive feedback from the FDA after the agency’s informal review of Petros’ technology component for self-selection.
Petros also announced that it has received positive feedback from the FDA after the agency’s informal review of Petros’ technology component for self-selection.
Attaining a tetrafecta composite outcome during radical nephroureterectomy (RNU) does not decrease the risk of cancer recurrence or increase overall
Zach Klaassen and Hanan Goldberg discuss the evolving landscape of nonmetastatic castration-resistant prostate cancer (nmCRPC), highlighting the impact of PSMA PET scans on diminishing this…
The FDA is set to have a decision regarding the subcutaneous nivolumab formulation on or by February 28, 2025.
Real-world data showed routine use of darolutamide regimens in community urology practice for patients with metastatic hormone-sensitive prostate cancer.
The American Urological Association (AUA) published the white paper, Catheter-Associated Urinary Tract Infections: Definitions and Significance in the Urologic Patient, in 2014. At that time,…
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Read our Cookies
AUA 2024, bladder cancer, Blue Light Cystoscopy, White Light Cystoscopy, Blue Light Cystoscopy Versus White Light Cystoscopy for the Detection of Bladder Cancer Using Modern…
In this study, patients with escalating clinical risk factors for recurrence did not have escalating 24-hour urine test abnormalities.
AUA 2024 SpaceOAR complications, MAUDE database, rectal wall infiltration, SpaceOAR Vue, Clavien-Dindo classification,
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.